Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519

Documenti analoghi

• Health status instruments for patients with COPD in pulmonary rehabilitation: defining a minimal clinically important difference
  di: Alma, Harma, et al.
  Pubblicazione: (2016)
• Thresholds for clinically important deterioration versus improvement in COPD health status: results from a randomised controlled trial in pulmonary rehabilitation and an observational study during routine clinical practice
  di: Alma, Harma Johanna, et al.
  Pubblicazione: (2019)
• The efficacy and safety of inhaled corticosteroids: are we ignoring the potential advantages of ciclesonide?
  di: van der Molen, Thys, et al.
  Pubblicazione: (2014)
• COPD management: role of symptom assessment in routine clinical practice
  di: van der Molen, Thys, et al.
  Pubblicazione: (2013)
• Putting health status guided COPD management to the test: protocol of the MARCH study
  di: Kocks, Janwillem, et al.
  Pubblicazione: (2013)